Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm™ [Yahoo! Finance]
Aquestive Therapeutics, Inc. (AQST)
Last aquestive therapeutics, inc. earnings: 3/11 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.aquestive.com/investor-relations
Company Research
Source: Yahoo! Finance
Remains well-capitalized and anticipates ending 2026 with significant cash Reiterates plans to submit in Canada and EU by the end of 2026 Company to host investor call on February 2, 2026, at 8:00am ET WARREN, N.J., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) on January 30, 2026 for the New Drug Application (NDA) seeking approval of Anaphylm™ (dibutepinephrine) Sublingual Film for the treatment of Type I allergic reactions, including anaphylaxis, in patients weighing 30kg or more (approximately 66 pounds). “While it is unfortunate to have received a CRL, we believe that, with the clarity we now have from the FDA, we have made significant progress towa
Show less
Read more
Impact Snapshot
Event Time:
AQST
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AQST alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AQST alerts
High impacting Aquestive Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AQST
News
- Aquestive Therapeutics, Inc. (NASDAQ:AQST) Analysts Just Trimmed Their Revenue Forecasts By 26% [Yahoo! Finance]Yahoo! Finance
- INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive TherapeuticsGlobeNewswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aquestive Therapeutics, Inc. - AQSTGlobeNewswire
- Leerink sees ‘silver lining' in Aquestive CRL given defined path to approval [Yahoo! Finance]Yahoo! Finance
- Aquestive Therapeutics (NASDAQ:AQST) was given a new $6.00 price target on by analysts at Lake Street Capital.MarketBeat
AQST
Earnings
- 11/5/25 - Miss
AQST
Sec Filings
- 2/2/26 - Form 8-K
- 1/21/26 - Form S-8
- 1/9/26 - Form 8-K
- AQST's page on the SEC website